Document Type
Article
Publication Date
10-2023
Identifier
DOI: 10.1038/s41372-023-01741-1; PMCID: PMC10541325
Abstract
OBJECTIVE: This study describes 3-year follow-up of 200 infants weighing ≥ 700 grams who underwent transcatheter patent ductus arteriosus (PDA) closure with the Amplatzer Piccolo™ Occluder.
STUDY DESIGN: Between June 2017 and February 2019, 200 children were enrolled in this U.S. study (NCT03055858). PDA closure, survival, and device- or procedure-related events were evaluated. A total of 156 of the available 182 patients (86%) completed the study.
RESULTS: The implant success rate was 95.5% (191/200). At 3 years, PDA closure was observed in 100% (33/33) of patients. Survival was >95% with 9 reported deaths. No deaths were adjudicated as device- or procedure-related. Notable events included aortic obstruction (2) requiring stent placement and tricuspid regurgitation (5), for which no interventions were required.
CONCLUSIONS: This follow-up study demonstrates high rates of PDA closure, low serious complication rates, and survival > 95% at 3 years. The Amplatzer Piccolo™ Occluder is a safe and effective therapy for PDA treatment in premature infants.
CLINICALTRIALS: gov identifier: NCT0305585.
Journal Title
Journal of perinatology : official journal of the California Perinatal Association
Volume
43
Issue
10
First Page
1238
Last Page
1244
MeSH Keywords
Infant; Humans; Child; Follow-Up Studies; Ductus Arteriosus, Patent; Prospective Studies; Cardiac Catheterization; Septal Occluder Device; Treatment Outcome
Keywords
Follow-Up Studies; Patent Ductus Arteriosus; Prospective Studies; Cardiac Catheterization; Septal Occluder Device; Treatment Outcome
Recommended Citation
Morray BH, Sathanandam SK, Forbes T, et al. 3-year follow-up of a prospective, multicenter study of the Amplatzer Piccolo™ Occluder for transcatheter patent ductus arteriosus closure in children ≥ 700 grams. J Perinatol. 2023;43(10):1238-1244. doi:10.1038/s41372-023-01741-1
Comments
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Publisher's Link: https://www.nature.com/articles/s41372-023-01741-1